# Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)

> **NCT05320159** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 17743 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Secukinumab

## Key facts

- **NCT ID:** NCT05320159
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-03
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 17743 (ACTUAL)
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05320159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05320159, "Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05320159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*